



Neuros Medical Secures \$56M Series D to Commercialize the Altius® System, an FDA-Approved, Non-Opioid Nerve Stimulation System for Chronic Post-Amputation Pain

NEWS PROVIDED BY

Neuros Medical

Jul 09, 2025, 08:00 ET

ALISO VIEJO, Calif., July 9, 2025 /PRNewswire/ -- Neuros Medical, Inc., the maker of the Altius® Direct Electrical Nerve Stimulation System, an FDA-approved, breakthrough non-opioid treatment for chronic post-amputation pain, today announced the closing of an oversubscribed \$56 million Series D financing round. The funding will support U.S. commercialization and further development of its groundbreaking Altius® Direct Electrical Nerve Stimulation System.

The round was led by new investor EQT Life Sciences, with participation from existing investors including US Venture Partners, Amzak Health, Osage University Partners, Sectoral Asset Management, Aperture Venture Partners and several long-standing and committed investors.

"I would like to thank our new and existing investors for their support in our mission to relieve pain and restore life for the millions of people suffering from chronic post-amputation pain," said David Veino, President & CEO, Neuros Medical. "This funding round is a strong validation of the unmet medical need in the amputee community and allows us to scale our commercial operations to expand access to this breakthrough technology, while equipping healthcare professionals with a non-opioid solution and support they need to deliver the highest standard of care."

Fouad Azzam, Ph.D., Partner in the EQT Life Sciences advisory team, commented: "Neuros Medical is addressing one of the most urgent and overlooked challenges in chronic pain management. EQT believes Altius has the potential to significantly improve the quality of life for amputees, and we are proud to partner with this team to bring the therapy to market."

About the Altius® Direct Electrical Nerve Stimulation System

The Altius® System is a patient-controlled, on-demand system that uses Neuros' patented technology to address the underlying cause of post-amputation pain by inhibiting pain signal transmission from the damaged peripheral nerves near the site of amputation to the central nervous system. The system consists of a nerve cuff electrode placed around an affected nerve and an implantable pulse generator (IPG). Patients initiate an on-demand 30-minute treatment session as needed for targeted pain relief.

The Altius System is FDA-approved and is indicated as an aid in the management of chronic intractable phantom and residual lower limb post-amputation pain in adult amputees. The Altius System is the only FDA-approved device that provides amputees with patient-controlled, on-demand relief by targeting the nerve pain directly.

[Click here for important safety information.](#)

About Neuros Medical, Inc.

There are nearly two million amputees in the U.S., with 300,000 new amputations occurring every year.¹ Post-amputation pain includes both phantom limb pain and residual limb pain, and impacts up to 80% of amputees, representing a significant unmet medical need, as existing treatment options are limited and consist primarily of opioids and gabapentinoids.² Neuros Medical is a privately held company and the maker of the Altius® Direct Electrical Nerve Stimulation System which is FDA-approved and is indicated as an aid in the management of chronic intractable phantom and residual lower limb post-amputation pain in adult amputees. Our mission is to reduce pain and restore life for people suffering with post-amputation pain. We are a passionate team guided by our core values and committed to our patients and the healthcare professionals who care for them.

Our Core Values: Patients First, Deliver Excellence, Responsible Ambition, Inspire and Empower.

References

1. Prevalence of Limb Loss and Limb Difference in the United States: Implications for Public Policy. Caruso and Harrington 2024 Avelere Report.
2. Erlenwein, J., Diers, M., Ernst, J., Schulz, F., & Petzke, F. (2021). Clinical updates on phantom limb pain. Pain reports, 6(1), e888.

For additional information regarding Neuros Medical, please contact:

Steve Bosrock, Vice President, Marketing

sbosrock@neurosmedical.com

www.neurosmedical.com

Tel: 440-951-2565

SOURCE Neuros Medical